Endo International plc is a global specialty pharmaceutical company focused on improving patients’ lives while creating value. Endo develops, manufactures, markets and distributes quality branded and generic pharmaceutical products as well as over-the-counter medications through its operating companies – Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs, SOMAR and Litha. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights, and assets from The DuPont Merck Pharmaceutical Company. Since that time, the company has expanded to include the following business segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals.
Endo’s strategy is to maximize value for our key stakeholders by employing a lean operating model with focused and disciplined execution that allows us to pursue growth opportunities both organically and through selective acquisitions. Additionally, we are leveraging a research and development model that focuses on lower risk, near-term projects. Our goal is to consistently create value for our shareholders while serving our patients and customers.
Endo has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 6,200 people worldwide*.
*As of 2/19/2016